Q.1 In Quillala bark, the dark patches often found on the surface are known as

a) Hydathodes

b) Rhytidoma

c) Raphides

d) Hypanthium

 

Q.2 A rhamno-glucoside on complete hydrolysis gives

a) Aglycone + Fructose + Rhamanose

b) Aglycone + Ribose + Rhamanose

c) Aglycone + Glucose + Rhamanose

d) Fructose + Rhamanose

 

Q.3 Which one of the following qualitative tests is not applied to cardiac glycoside

a) Killer Killiani

b) Baljet

c) Borntreger

d) Legal

 

Q.4 The active constituent present in Picrorrhyza kurroa is

a) Ascaridole

b) Cabenoxolone

c) Kutkosides

d) Khellin

 

Q.5 The leaves of a plant are obovate in shape with tapering apex and show papillose cells in lower epidermis. They contained 1 percent of anthraquinone glycosides. It could be

a) Dog Senna

b) Palthe Senna

c) Cassia Senna

 

d) Tinnyvelly Senna

Q.6 The rate of drug administration that gives the most rapid onset of the pharmacologic effect is

a) per oral administration

b) intradermal injection

c) intravenous injection

d) subcutaneous injection

 

Q.7 Dose dumping is a problem in the formulation of

a) soft gelatin capsule

b) compressed tablets

c) hard gelatin capsule

d) modified release drug products

 

Q.8 The extent of ionization of weak electrolyte drug is dependent on the

a) Particle size and surface area of the drug

b) Noyes – Whitney equation for the drug

c) polymeric form of the drug

d) pH of the media and pKa of the drug

 

Q.9 The characteristics of an active transport include all of the following except:

a) active transport moves drug molecules against concentration gradient

b) active transport follows Fick’s law of diffusion

c) active transport requires energy

d) active transport of drug molecules may be saturated at high drug concentration

 

Q.10 In order to determine the absolute bioavailability of a drug given as an oral extended-release tablet, the bioavailability of the drug must be compared to the bioavailability of the drug from

a) an immediate-release oral tablet containing the same amount of the active ingredient

b) a reference (brand) extended-release tablet that is a pharmaceutical equivalent

c) a parenteral solution of the drug given by IV bolus or IV infusion

d) an oral solution of the drug in the same dose

 


1.b      2.c      3.c     4.c        5.a   6.c        7.d          8.d          9.d         10.c